Latest news with #Wounds
Daily Record
a day ago
- Entertainment
- Daily Record
Little-known Netflix horror is 'certified fresh' with 5-star rating
Under The Shadow is a completely original take on horror and is a must-watch for all fans of the genre, with the Persian language film being described as a 'future horror classic' For those who enjoy a good scare, Netflix has a hidden gem that's been described as a future horror movie classic. Under The Shadow, with its rave reviews, is definitely worth your time. This unique horror film is set in 1980s post-revolutionary Tehran during the war. It follows the story of medical student Shideh, barred from continuing her studies, and her daughter Dorsa, left alone after her husband is drafted into military service. Most of the film unfolds within their apartment, amidst falling missiles. A superstitious neighbour suggests that the bombs carry cursed spirits. Soon, Shideh becomes convinced that a supernatural entity is possessing her daughter, leading to a struggle against both natural and supernatural forces. Despite its unique premise, the film still delivers classic horror thrills - sudden window breaks or even a popping toaster are enough to make you jump and keep you on edge for a nerve-wracking hour and a half, reports the Mirror US. The film's cinematography, released in 2016, sets it apart, leaving viewers thoroughly unnerved and questioning which horrors are real and which are imagined. Under The Shadow marks the directorial debut of British-Iranian filmmaker Babak Anvari, paving the way for his subsequent releases - Wounds, starring Armie Hammer and Dakota Johnson, and I Came By, featuring George MacKay and Hugh Bonneville. The film Under the Shadow garnered widespread acclaim, boasting an impressive 99% 'certified fresh' rating on Rotten Tomatoes. The Observer film critic Mark Kermode showered it with praise, awarding it five stars and writing: "With this terrific feature debut, Anvari lifts the veil on his heroines' hidden lives and leaves us all dreaming with our eyes wide open." Selected as the British entry for the Best Foreign Language Film at the Oscars, the Persian language film received overwhelmingly positive reviews from critics. However, some audience members were more divided. One viewer gave the film three stars on Google Reviews, stating: "Under the Shadow is a unique blend of horror and historical context. While it had its moments of brilliance, I can't help but feel that it didn't fully live up to its potential." In contrast, another reviewer awarded it five stars, writing: "Wow. just amazing. A perfect example of a well-written, directed movie. The acting, VFX, sound design and production design etc are worth mentioning. Watch it on a cold dark night, when you are alone, this gave me a real chill. ""The brilliance is that, for a normal audience, it's a scary, horror movie, but, for those who search beyond, there are metaphors and beyond just a horror movie. ".
Yahoo
13-05-2025
- Health
- Yahoo
MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers
Post hoc analysis published in the peer-reviewed journal Wounds highlights EscharEx®'s superior clinical performance and comparable safety profile to SANTYL® YAVNE, Israel, May 13, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced the publication of a peer-reviewed post hoc analysis in Wounds. The analysis is based on data from the Company's Phase II ChronEx clinical trial in patients with venous leg ulcers (VLUs) evaluating the efficacy and safety of EscharEx® compared with collagenase ointment (SANTYL®), the only FDA-cleared enzymatic debridement agent commercially available for the treatment of dermal ulcers. The article, titled 'Bromelain-Based Debridement Versus Collagenase Ointment Debridement of Venous Leg Ulcers: Post Hoc Analysis of the ChronEx Trial,' appears in the April 2025 edition of Wounds (Index 2025;37(4):166–173) and compares outcomes in a subgroup of patients from the non-surgical standard of care arm treated with SANTYL (n=8) to those treated with EscharEx (n=46). 'These new findings are consistent with my prior experience using EscharEx in clinical trials and SANTYL in clinical practice,' said Dr. Cyaandi Dove, DPM, of the University of Texas Health Science Center at San Antonio and co-author of the publication. 'Compared to SANTYL, EscharEx achieved faster and more effective debridement and promoted healthier granulation tissue, both key to optimal wound bed preparation. EscharEx's enzymatic formulation targets a wider range of non-viable and necrotic tissue, which may account for the favorable clinical outcomes observed.' Key findings from the post hoc analysis include: Debridement Efficacy: Complete debridement at 2 weeks was achieved in 63% of EscharEx-treated patients, compared to 0% in the SANTYL group (p = 0.001). Median time to debridement was 9 days for EscharEx vs. not achieved for SANTYL (p = 0.023). Wound Bed Preparation (WBP): WBP—defined as complete debridement and complete granulation—was achieved by 50% of EscharEx patients in 2 weeks vs. 0% with SANTYL (p = 0.015). Over the entire study period (12 weeks), 78% of EscharEx patients achieved WBP vs. 38% with SANTYL (p = 0.03). Median time to WBP: 11 days for EscharEx; not achieved for SANTYL (p = 0.014). Wound Closure: Closure was achieved in 33% of EscharEx patients vs. 25% with SANTYL (not statistically significant). Among those who closed, the mean time to closure was 48 days for EscharEx vs. 76 days with SANTYL (p = 0.05). Safety and Tolerability: Adverse event rates and applicational pain were similar between groups. Deep wound infection, assessed using recognized clinical criteria, occurred in 11% of EscharEx patients compared to 38% in the SANTYL group. About EscharEx® EscharEx® is a bromelain-based, bioactive enzymatic therapy in advanced clinical development for the debridement of chronic and hard-to-heal wounds. Designed for topical, once-daily application, EscharEx has demonstrated a favorable safety profile and effective wound bed preparation in multiple Phase II trials. The therapy has shown the ability to remove non-viable tissue, promote granulation tissue, and reduce bioburden and biofilm. A global Phase III study in venous leg ulcers (VLUs) is currently underway, with a clinical study in diabetic foot ulcers (DFUs) in preparation. EscharEx has shown clinical advantages over the leading enzymatic debridement product and targets a substantial global market opportunity. About MediWound Ltd. MediWound Ltd. (Nasdaq: MDWD) is a global biotechnology company focused on developing and commercializing enzymatic therapies for non-surgical tissue repair. The company's FDA-approved biologic, NexoBrid®, is indicated for the enzymatic removal of eschar in thermal burns and is marketed in the U.S., European Union, Japan, and other international markets. MediWound is also advancing EscharEx®, a late-stage investigational therapy for the debridement of chronic wounds. EscharEx has demonstrated clinical advantages over the leading enzymatic debridement product and targets a substantial global market opportunity. For more information, visit and follow us on LinkedIn. Cautionary Note Regarding Forward-Looking Statements MediWound cautions you that all statements other than statements of historical fact included in this press release that address activities, events, or developments that we expect, believe, or anticipate will or may occur in the future are forward-looking statements. Although we believe that we have a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting us and are subject to risks, assumptions, uncertainties, and factors, all of which are difficult to predict and many of which are beyond our control. Actual results may differ materially from those expressed or implied by the forward-looking statements in this press release. These statements are often, but are not always, made through the use of words or phrases such as 'anticipates,' 'intends,' 'estimates,' 'plans,' 'expects,' 'continues,' 'believe,' 'guidance,' 'outlook,' 'target,' 'future,' 'potential,' 'goals' and similar words or phrases, or future or conditional verbs such as 'will,' 'would,' 'should,' 'could,' 'may,' or similar this press release contains forward-looking statements concerning the anticipated progress, development, study design, expected data timing, objectives anticipated timelines, expectations and commercial potential of our products and product candidates, including EscharEx®. Among the factors that may cause results to be materially different from those stated herein are the inherent uncertainties associated with the uncertain, lengthy and expensive nature of the product development process; the timing and conduct of our studies of our products and product candidates, including the timing, progress and results of current and future clinical studies, and our research and development programs; the approval of regulatory submission by the FDA, the European Medicines Agency or by any other regulatory authority, our ability to obtain marketing approval of our products and product candidates in the U.S. or other markets; the clinical utility, potential advantages and timing or likelihood of regulatory filings and approvals of our products and products; our expectations regarding future growth, including our ability to develop new products; market acceptance of our products and product candidates; our ability to maintain adequate protection of our intellectual property; competition risks; the need for additional financing; the impact of government laws and regulations and the impact of the current global macroeconomic climate on our ability to source supplies for our operations or our ability or capacity to manufacture, sell and support the use of our products and product candidates in the future. These and other significant factors are discussed in greater detail in MediWound's annual report on Form 20-F for the year ended December 31, 2024, filed with the Securities and Exchange Commission ('SEC') on March 19, 2025 and Quarterly Reports on Form 6-K and other filings with the SEC from time-to-time. These forward-looking statements reflect MediWound's current views as of the date hereof and MediWound undertakes, and specifically disclaims, any obligation to update any of these forward-looking statements to reflect a change in their respective views or events or circumstances that occur after the date of this release except as required by law. MediWound Contacts:Hani LuxenburgChief Financial OfficerMediWound Daniel FerryManaging DirectorLifeSci Advisors, LLCdaniel@ Media Contact:Ellie HansonFINN Partners for Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
08-04-2025
- Health
- Associated Press
WHS receives record number of abstracts; event to feature First-To-Podium research
Wound care research accepted at HMP Global symposium to be published in industry-leading Wounds journal, showcasing the latest innovations in wound care. 'As the world's leading wound care event, SAWC Spring | WHS continues to push the boundaries and make a difference in wound care together through research, education, innovation, and collaboration.' — John C. Lantis II, MD, FACS, Editor-in-Chief of Wounds MALVERN, PA, UNITED STATES, April 8, 2025 / / -- The Symposium on Advanced Wound Care (SAWC) Spring | Wound Healing Society (WHS) received a record-breaking number of abstract submissions for its 2025 meeting, solidifying its position as the top forum for wound care innovation and education. The educational program at the HMP Global event will feature First-To-Podium presentations of practice-changing research from the leading minds in the field. SAWC Spring | WHS will be held April 30-May 4 in Grapevine, Texas. Abstracts accepted for presentation will also be published in the industry-leading Wounds journal, the most widely read, peer-reviewed journal focusing on wound care and wound research. Wounds is the official publication for SAWC and is indexed in MEDLINE/PubMED. SAWC Spring received 413 abstract submissions, with an additional 73 submitted to WHS. That unprecedented number of abstract submissions surpasses the record SAWC Fall number of 391 submissions and the SAWC Spring 2024 number of 378 submissions. 'The increasing number of submitted abstracts reflects the growing interest and advancements in wound care research,' said John C. Lantis II, MD, FACS, Editor-in-Chief of Wounds. 'As the world's leading wound care event, SAWC Spring | WHS continues to push the boundaries and make a difference in wound care together through research, education, innovation, and collaboration.' The First-To-Podium presentations, Abstract & Founders Award ceremony will take place on Friday, May 2, at 7:15 p.m., followed by the Poster Reception. Lantis noted that these presentations will highlight some of the most impactful and innovative research in wound care. Abstracts span a wide range of categories, including case studies, laboratory and clinical research, evidence-based practice, practice innovations and health economics. Posters will be on display in the Poster Hall on Friday, May 2, and Saturday, May 3, from 7:30 a.m. to 5 p.m., and on multimedia screens throughout the conference space. ePosters will also be available for viewing in the mobile app, ensuring attendees have ample opportunities to engage with the latest research. Educational Program SAWC Spring | WHS 2025 will deliver more than 80 high-impact sessions led by over 200 faculty experts. The Exhibit Hall will feature scores of industry supporters showcasing the latest wound care technology, equipment and services. The partnership between WHS and SAWC Spring amplifies the power of collaboration: 'The relationship between the SAWC Spring and WHS is advancing patient care, fueling research and fostering the exchange of ideas and best practices, said Tiffney Oliver, Vice President, Wound Care Learning Network, HMP Education. In addition to a WHS annual meeting track at SAWC Spring/WHS, the Wound Care Business Navigator will dive into the realities of delivering healthcare beyond the clinical scope, focusing on critical business topics including coding, coverage and payment, regulations and more. Designed for a wide range of healthcare professionals, including physicians, nursing professionals, podiatrists, physician assistants, physical therapists, researchers, scientists, dietitians, and healthcare marketing and sales professionals as well as medical students, residents and fellows, SAWC Spring | WHS offers a spectrum of educational and networking opportunities. For more information or to register, visit the SAWC Spring | WHS website. About HMP Global HMP Global is the omnichannel market leader in healthcare events, education, and insight — with a mission to improve patient care. For 40 years, the company has built trusted brands including Psych Congress, the premier source for mental health education, and the Symposium on Advanced Wound Care (SAWC), the largest wound care meeting in the world. HMP Global partners with leading experts around the world to deliver more than 450 annual events, medical strategy, and marketing for pharmaceutical and medical device customers through HMP Collective, and pharmaceutical market insight, engaging a global community of healthcare stakeholders that includes nearly 2 million clinicians across 600 medical specialties as well as managed care, behavioral health, senior living, emergency medical, and pharmaceutical commercialization professionals. For more information, follow HMP Global on LinkedIn or visit Sandi Beason, APR Legal Disclaimer:
